LYTIR

Insider · SEC Form 4 · Director, 10% Owner

RA CAPITAL MANAGEMENT, L.P.

In the 12 months to Nov 19, 2026, on the open market: bought $532.2M of PBLS, BBTX, PEPG and 3 more; sold $94.7M of SEPN, SION, LENZ and 1 more. Filed a median of 2 business days after the trade.

Open-market purchases and sales this filer reported on SEC Form 4, by the day traded. Insiders have two business days to file. A sale marked 10b5-1 was made under a plan adopted in advance. How to read these

Insider purchases and sales, by month (last 12 months)Insider purchases: $532.2M in total; Insider sales: $94.7M in total.Jun: Insider purchases $430.4MJun: Insider sales $320KJul: Insider purchases $12.0MAug: Insider sales $63.5MSep: Insider sales $21.8MOct: Insider purchases $6.6MOct: Insider sales $9.1MNov: Insider purchases $83.2MDecJanFebMarAprMayJunJulAugSepOctNov$430.4M$63.5M
Insider purchases above the line: $532.2MInsider sales below: $94.7M
Dollar value of open-market purchases and sales reported on SEC Form 4, by the month traded. Sales include pre-arranged 10b5-1 plan sales.
  1. SGPBought: SpyGlass Pharma, Inc. Nov 16, 2026 1,000 shares filed Nov 18, 2026 5,967,439 shares held indirectly after, as filed filing $32K
  2. PEPGBought: PepGen Inc. Nov 13, 2026 8,625,000 shares filed Nov 17, 2026 27,179,273 shares held indirectly after, as filed filing $43.1M
  3. BBTXBought: Bambusa Therapeutics, Inc. Nov 2, 2026 2,500,000 shares filed Nov 3, 2026 2 transactions filing $40.0M
  4. BBTXBought: Bambusa Therapeutics, Inc. Oct 30, 2026 453,820 shares filed Nov 3, 2026 2 transactions filing $6.6M
  5. LENZSold: LENZ Therapeutics, Inc. Oct 29, 2026 2,718,684 shares filed Nov 2, 2026 3 transactions filing $9.1M
  6. SIONSold: Sionna Therapeutics, Inc. Sep 17, 2026 3,448,811 shares filed Sep 21, 2026 2 transactions filing $21.8M
  7. SEPNSold: Septerna, Inc. Aug 12, 2026 1,493,000 shares filed Aug 14, 2026 2 transactions filing $63.5M
  8. ARTVBought: Artiva Biotherapeutics, Inc. Jul 31, 2026 24,944 shares filed Jul 31, 2026 17,329,570 shares held indirectly after, as filed filing $248K
  9. ARTVBought: Artiva Biotherapeutics, Inc. Jul 29, 2026 20,824 shares filed Jul 31, 2026 17,304,626 shares held indirectly after, as filed filing $208K
  10. ARTVBought: Artiva Biotherapeutics, Inc. Jul 24, 2026 41,319 shares filed Jul 28, 2026 17,283,802 shares held indirectly after, as filed filing $413K
  11. ARTVBought: Artiva Biotherapeutics, Inc. Jul 23, 2026 59,880 shares filed Jul 23, 2026 17,242,483 shares held indirectly after, as filed filing $596K
  12. PBLSBought: Parabilis Medicines, Inc. Jul 22, 2026 47,250 shares filed Jul 22, 2026 26,529,686 shares held indirectly after, as filed filing $1.4M
  13. ARTVBought: Artiva Biotherapeutics, Inc. Jul 22, 2026 84,124 shares filed Jul 23, 2026 17,182,603 shares held indirectly after, as filed filing $835K
  14. PBLSBought: Parabilis Medicines, Inc. Jul 21, 2026 65,923 shares filed Jul 22, 2026 3 transactions filing $1.9M
  15. ARTVBought: Artiva Biotherapeutics, Inc. Jul 21, 2026 120,582 shares filed Jul 23, 2026 17,098,479 shares held indirectly after, as filed filing $1.2M
  16. PBLSBought: Parabilis Medicines, Inc. Jul 20, 2026 131,420 shares filed Jul 22, 2026 2 transactions filing $3.6M
  17. ARTVBought: Artiva Biotherapeutics, Inc. Jul 17, 2026 7,882 shares filed Jul 20, 2026 16,977,927 shares held indirectly after, as filed filing $71K
  18. ARTVBought: Artiva Biotherapeutics, Inc. Jul 16, 2026 152,472 shares filed Jul 20, 2026 16,970,045 shares held indirectly after, as filed filing $1.4M
  19. ARTVBought: Artiva Biotherapeutics, Inc. Jul 13, 2026 6,522 shares filed Jul 23, 2026 16,817,543 shares held indirectly after, as filed filing $58K
  20. ARTVBought: Artiva Biotherapeutics, Inc. Jul 10, 2026 15,102 shares filed Jul 14, 2026 16,811,021 shares held indirectly after, as filed filing $135K
  21. ARTVBought: Artiva Biotherapeutics, Inc. Jun 26, 2026 1,876 shares filed Jun 29, 2026 16,795,919 shares held indirectly after, as filed filing $17K
  22. ARTVBought: Artiva Biotherapeutics, Inc. Jun 25, 2026 31,000 shares filed Jun 29, 2026 16,794,043 shares held indirectly after, as filed filing $275K
  23. HOWLSold: Werewolf Therapeutics, Inc. Jun 17, 2026 416,911 shares filed Jun 22, 2026 2 transactions filing $146K
  24. COAGBought: Hemab Therapeutics Holdings, Inc. Jun 16, 2026 61,523 shares filed Jun 17, 2026 6,444,637 shares held indirectly after, as filed filing $1.5M
  25. ARTVBought: Artiva Biotherapeutics, Inc. Jun 16, 2026 124,893 shares filed Jun 16, 2026 16,763,043 shares held indirectly after, as filed filing $1.1M
  26. HOWLSold: Werewolf Therapeutics, Inc. Jun 16, 2026 149,625 shares filed Jun 16, 2026 2 transactions filing $55K
  27. COAGBought: Hemab Therapeutics Holdings, Inc. Jun 15, 2026 6,146 shares filed Jun 17, 2026 6,383,114 shares held indirectly after, as filed filing $153K
  28. ARTVBought: Artiva Biotherapeutics, Inc. Jun 15, 2026 15,414 shares filed Jun 16, 2026 16,638,150 shares held indirectly after, as filed filing $139K
  29. HOWLSold: Werewolf Therapeutics, Inc. Jun 15, 2026 128,770 shares filed Jun 16, 2026 2 transactions filing $50K
  30. ARTVBought: Artiva Biotherapeutics, Inc. Jun 12, 2026 391,019 shares filed Jun 16, 2026 16,622,736 shares held indirectly after, as filed filing $3.4M
  31. HOWLSold: Werewolf Therapeutics, Inc. Jun 12, 2026 170,441 shares filed Jun 16, 2026 2 transactions filing $68K
  32. PBLSBought: Parabilis Medicines, Inc. Jun 11, 2026 21,188,750 shares filed Jun 15, 2026 2 transactions filing $423.8M

Source: SEC Form 4 filings. Value is shares × the price reported on the filing; a filing whose price failed Lytir's check against the market price is left out, and a trade that related owners reported on separate forms is counted once. Filings can be late, amended or wrong at the source; see methodology.

Stakes filed (13D/13G)

Anyone who comes to hold more than 5% of a company's voting shares must tell the SEC. A Schedule 13D is filed by a holder who may seek to influence the company; a 13G by one who states it is a passive investor. An amendment updates an earlier filing, and a stake reported as 0% means the holder says it has sold all, or nearly all, of its shares. Filings made under this filer's SEC CIK in the same 12 months, newest first; the figure is the percentage the filing states. Every recent 13D and 13G

  1. PEPGRA Capital Management, L.P. filed Nov 17, 2026 Schedule 13D/A may seek influence 28,742,212 shares issuer: PEPGEN INC. filing 30.5%
  2. PALIRA Capital Management, L.P. filed Nov 16, 2026 Schedule 13G/A passive issuer: Palisade Bio, Inc. filing 9.9%
  3. KPTIRA Capital Management, L.P. filed Nov 16, 2026 Schedule 13G/A passive issuer: Karyopharm Therapeutics Inc. filing 9.9%
  4. QTTBRA Capital Management, L.P. filed Nov 16, 2026 Schedule 13G/A passive issuer: Q32 Bio Inc. filing 9.9%
  5. CCCCRA Capital Management, L.P. filed Nov 16, 2026 Schedule 13G/A passive issuer: C4 Therapeutics, Inc. filing 9.9%
  6. EQRA Capital Management, L.P. filed Nov 16, 2026 Schedule 13G/A passive issuer: EQUILLIUM, INC. filing 9.9%
  7. UNCYRA Capital Management, L.P. filed Nov 16, 2026 Schedule 13G/A passive issuer: Unicycive Therapeutics, Inc. filing 9.9%
  8. TSHARA Capital Management, L.P. filed Nov 16, 2026 Schedule 13G/A passive issuer: TAYSHA GENE THERAPIES, INC. filing 9.9%
  9. NAMSRA Capital Management, L.P. filed Nov 16, 2026 Schedule 13G/A passive issuer: NewAmsterdam Pharma Company N.V. filing 9.9%
  10. OVIDRA Capital Management, L.P. filed Nov 16, 2026 Schedule 13G/A passive issuer: OVID THERAPEUTICS INC. filing 7.8%
  11. GHRSRA Capital Management, L.P. filed Nov 16, 2026 Schedule 13G/A passive issuer: GH Research PLC filing 5.3%
  12. JBIORA Capital Management, L.P. filed Nov 16, 2026 Schedule 13G/A passive issuer: Jade Biosciences, Inc. filing 2.9%
  13. ZLABRA Capital Management, L.P. filed Nov 16, 2026 Schedule 13G/A passive issuer: Zai Lab Limited filing 2.5%
  14. BCRXRA Capital Management, L.P. filed Nov 16, 2026 Schedule 13G/A passive issuer: BioCryst Pharmaceuticals, Inc. filing 0%
  15. EVMNRA Capital Management, L.P. filed Nov 10, 2026 Schedule 13D/A may seek influence 3,494,638 shares issuer: Evommune, Inc. filing 8.5%
  16. CLYMRA Capital Management, L.P. filed Nov 9, 2026 Schedule 13D/A may seek influence 23,941,277 shares issuer: Climb Bio, Inc. filing 33%
  17. BBTXRA Capital Management, L.P. filed Nov 6, 2026 Schedule 13D may seek influence 7,429,758 shares issuer: Bambusa Therapeutics, Inc. filing 14.6%
  18. SLDBRA Capital Management, L.P. filed Nov 6, 2026 Schedule 13D/A may seek influence 12,036,126 shares issuer: SOLID BIOSCIENCES INC. filing 10.8%
  19. LENZRA Capital Management, L.P. filed Nov 2, 2026 Schedule 13D/A may seek influence 70,533 shares issuer: LENZ THERAPEUTICS, INC. filing 0.2%
  20. TCXBRA Capital Management, L.P. filed Oct 26, 2026 Schedule 13G passive issuer: TCGX Acquisition Corp. II filing 7.2%
  21. ALECRA Capital Management, L.P. filed Oct 26, 2026 Schedule 13G passive issuer: Alector, Inc. filing 5.1%
  22. FLSCRA Capital Management, L.P. filed Oct 22, 2026 Schedule 13G passive issuer: Frazier Life Sciences Acquisition Corp. II filing 9%
  23. CRBPRA Capital Management, L.P. filed Sep 30, 2026 Schedule 13G passive issuer: Corbus Pharmaceuticals Holdings, Inc. filing 9.9%
  24. BETRFRA Capital Management, L.P. filed Sep 22, 2026 Schedule 13G passive issuer: BetterLife Pharma Inc. filing 9%
  25. SIONRA Capital Management, L.P. filed Sep 21, 2026 Schedule 13D/A may seek influence 6,476,193 shares issuer: SIONNA THERAPEUTICS, INC. filing 14.3%
  26. TYRARA Capital Management, L.P. filed Sep 17, 2026 Schedule 13D/A may seek influence 14,130,492 shares issuer: TYRA BIOSCIENCES, INC. filing 19.9%
  27. JTTTRA Capital Management, L.P. filed Sep 3, 2026 Schedule 13G passive issuer: JATT III Acquisition Corp filing 5.1%
  28. LTGORA CAPITAL MANAGEMENT, L.P. filed Aug 17, 2026 Schedule 13G passive issuer: Latigo Biotherapeutics, Inc. filing 8.4%
  29. SEPNRA CAPITAL MANAGEMENT, L.P. filed Aug 14, 2026 Schedule 13D/A may seek influence 5,525,324 shares issuer: Septerna, Inc. filing 11.8%
  30. TSHARA Capital Management, L.P. filed Aug 14, 2026 Schedule 13G/A passive issuer: TAYSHA GENE THERAPIES, INC. filing 9.9%
  31. ACETRA Capital Management, L.P. filed Aug 14, 2026 Schedule 13G/A passive issuer: Adicet Bio, Inc. filing 9.9%
  32. RANIRA Capital Management, L.P. filed Aug 14, 2026 Schedule 13G/A passive issuer: RANI THERAPEUTICS HOLDINGS, INC. filing 9.9%
  33. GERNRA Capital Management, L.P. filed Aug 14, 2026 Schedule 13G/A passive issuer: GERON CORPORATION filing 9.9%
  34. OVIDRA Capital Management, L.P. filed Aug 14, 2026 Schedule 13G/A passive issuer: OVID THERAPEUTICS INC. filing 9.9%
  35. CCCCRA Capital Management, L.P. filed Aug 14, 2026 Schedule 13G/A passive issuer: C4 Therapeutics, Inc. filing 9.9%
  36. KPTIRA Capital Management, L.P. filed Aug 14, 2026 Schedule 13G/A passive issuer: Karyopharm Therapeutics Inc. filing 9.9%
  37. ACRSRA Capital Management, L.P. filed Aug 14, 2026 Schedule 13G/A passive issuer: ACLARIS THERAPEUTICS, INC. filing 9.1%
  38. CRVORA Capital Management, L.P. filed Aug 14, 2026 Schedule 13G/A passive issuer: CervoMed Inc. filing 8.6%
  39. EWTXRA Capital Management, L.P. filed Aug 14, 2026 Schedule 13G/A passive issuer: Edgewise Therapeutics, Inc. filing 7.8%
  40. GHRSRA Capital Management, L.P. filed Aug 14, 2026 Schedule 13G/A passive issuer: GH Research PLC filing 7.1%
  41. AVTXRA Capital Management, L.P. filed Aug 14, 2026 Schedule 13G/A passive issuer: Avalo Therapeutics, Inc. filing 6.3%
  42. BCRXRA Capital Management, L.P. filed Aug 14, 2026 Schedule 13G/A passive issuer: BioCryst Pharmaceuticals, Inc. filing 6.2%
  43. FULCRA Capital Management, L.P. filed Aug 14, 2026 Schedule 13G/A passive issuer: FULCRUM THERAPEUTICS, INC. filing 0%
  44. RNARA Capital Management, L.P. filed Aug 14, 2026 Schedule 13G/A passive issuer: Atrium Therapeutics, Inc. filing 0%
  45. TCGXRA Capital Management, L.P. filed Aug 13, 2026 Schedule 13G passive issuer: TCGX Acquisition Corp. filing 5.5%
  46. WVERA CAPITAL MANAGEMENT, L.P. filed Aug 11, 2026 Schedule 13D/A may seek influence 34,314,406 shares issuer: Wave Life Sciences, Inc. filing 16.8%
  47. SABSRA CAPITAL MANAGEMENT, L.P. filed Aug 10, 2026 Schedule 13D/A may seek influence 9,609,852 shares issuer: SAB Biotherapeutics, Inc. filing 9.9%
  48. OBXRA Capital Management, L.P. filed Aug 10, 2026 Schedule 13G passive issuer: Obsidian Therapeutics, Inc. filing 9.7%
  49. INORA CAPITAL MANAGEMENT, L.P. filed Aug 7, 2026 Schedule 13G passive issuer: INOVIO PHARMACEUTICALS, INC. filing 9.9%
  50. DBVTRA Capital Management, L.P. filed Aug 6, 2026 Schedule 13G passive issuer: DBV TECHNOLOGIES S.A. filing 5.8%
  51. SCTXRA Capital Management, L.P. filed Aug 3, 2026 Schedule 13G passive issuer: Scribe Therapeutics Inc. filing 9.6%
  52. CAPRRA Capital Management, L.P. filed Aug 3, 2026 Schedule 13G passive issuer: Capricor Therapeutics, Inc. filing 5.2%
  53. IKTRA Capital Management, L.P. filed Jul 31, 2026 Schedule 13G/A passive issuer: Inhibikase Therapeutics, Inc. filing 9.9%
  54. ARTVRA CAPITAL MANAGEMENT, L.P. filed Jul 23, 2026 Schedule 13D/A may seek influence 18,415,956 shares issuer: Artiva Biotherapeutics, Inc. filing 37.9%
  55. PCSCRA CAPITAL MANAGEMENT, L.P. filed Jul 22, 2026 Schedule 13D/A may seek influence 15,367,270 shares issuer: Freenome, Inc. filing 14.3%
  56. VORRA CAPITAL MANAGEMENT, L.P. filed Jul 21, 2026 Schedule 13D/A may seek influence 12,937,855 shares issuer: Vor Biopharma Inc. filing 19.9%
  57. AGENRA CAPITAL MANAGEMENT, L.P. filed Jul 20, 2026 Schedule 13G passive issuer: AGENUS INC filing 9.9%
  58. CLYMRA CAPITAL MANAGEMENT, L.P. filed Jul 7, 2026 Schedule 13D/A may seek influence 23,249,186 shares issuer: Climb Bio, Inc. filing 33%
  59. HOWLRA CAPITAL MANAGEMENT, L.P. filed Jul 2, 2026 Schedule 13D/A may seek influence 1,985,541 shares issuer: Werewolf Therapeutics, Inc. filing 4.1%
  60. HOWLRA CAPITAL MANAGEMENT, L.P. filed Jun 26, 2026 Schedule 13D/A may seek influence 2,915,742 shares issuer: Werewolf Therapeutics, Inc. filing 6%
  61. SLDBRA CAPITAL MANAGEMENT, L.P. filed Jun 24, 2026 Schedule 13D/A may seek influence 12,036,126 shares issuer: Solid Biosciences Inc. filing 11.9%
  62. HOWLRA CAPITAL MANAGEMENT, L.P. filed Jun 22, 2026 Schedule 13D/A may seek influence 3,654,307 shares issuer: Werewolf Therapeutics, Inc. filing 7.5%
  63. PBLSRA CAPITAL MANAGEMENT, L.P. filed Jun 18, 2026 Schedule 13D may seek influence 28,933,371 shares issuer: Parabilis Medicines, Inc. filing 23.8%
  64. ARTVRA CAPITAL MANAGEMENT, L.P. filed Jun 15, 2026 Schedule 13D/A may seek influence 17,811,623 shares issuer: Artiva Biotherapeutics, Inc. filing 36.6%
  65. HOWLRA CAPITAL MANAGEMENT, L.P. filed Jun 15, 2026 Schedule 13D/A may seek influence 5,138,703 shares issuer: Werewolf Therapeutics, Inc. filing 10.6%

Other Form 4 entries

Not counted above: entries this filer reported on Form 4 in the same 12 months that are not open-market purchases or sales. Each entry is one line of a filing.

  • FRNM: grant or award (code A), 7 entries, Jul 20, 2026
  • CLYM: option exercise or conversion (code M), 4 entries, Sep 28, 2026
  • BBTX: conversion (code C), 2 entries, Nov 2, 2026
  • PBLS: conversion (code C), 2 entries, Jun 11, 2026
  • VOR: option exercise or conversion (code M), 2 entries, Aug 24 to Oct 2, 2026
  • IKT: other acquisition or disposition (code J), 1 entry, Jul 29, 2026
  • VOR: in-the-money exercise (code X), 1 entry, Jul 16, 2026
  • WVE: grant or award (code A), 1 entry, Oct 5, 2026
Code A
A grant or award from the company, such as stock given as pay.
Code C
A conversion of a derivative security, such as preferred stock or units, into shares.
Code J
Another acquisition or disposition, described in the filing's footnotes.
Code M
An exercise or conversion of a derivative security received from the company, such as stock options.
Code X
An exercise of an in-the-money or at-the-money derivative security.

Source: the same SEC Form 4 filings. The codes are the SEC's own transaction codes; the meanings above are a plain-words reading of the SEC's Form 4 instructions.